Eton Pharmaceuticals is a high-quality specialty drug maker growing revenue 99% YoY with a 9/9 Piotroski F-Score and 21.5% upside to the analyst target, but insiders have sold $13.9M in 90 days (0.969% of market cap) and the earnings record is uneven.
Thesis pillars
- Explosive Revenue Growth→Stable
- High Quality Returns→Stable
- Heavy Insider Selling→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 19, 2026
Eton Pharmaceuticals, Inc. (ETON) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $49.51. Insider activity concern; also weak momentum, recent C-suite change — blocks BUY_NOW at $51.80. Engine's entry $49.51 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Consecutive earnings misses (2).
Eton Pharmaceuticals is a commercial-stage rare-disease pharmaceutical company with eight marketed products across pediatric endocrinology (INCRELEX, ALKINDI SPRINKLE, KHINDIVI) and metabolic disorders (GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, Nitisinone), plus... Read more
Wait for pullback to $49.51. Insider activity concern; also weak momentum, recent C-suite change — blocks BUY_NOW at $51.80. Engine's entry $49.51 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Consecutive earnings misses (2). Chart setup: No clear chart pattern; technical signals are mixed. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.01, quality 7.8/10, growth 10.0/10). | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Score 6.3/10, moderate confidence.
Passes 5/9 gates (positive momentum, favorable risk/reward ratio, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: aggressive.
About Eton Pharmaceuticals, Inc.
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals markets eight rare-disease products spanning pediatric endocrinology (INCRELEX, ALKINDI SPRINKLE, KHINDIVI) and metabolic disorders (GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, Nitisinone), most acquired and relaunched under Eton's own commercial infrastructure since 2020. INCRELEX targets patients with severe primary IGF-1 deficiency across 40 territories, ALKINDI SPRINKLE addresses an estimated 10,000 U.S. children with adrenal insufficiency, and pipeline candidate ET-600 carries an FDA PDUFA target action date of February 25, 2026.
Eton's model centers on acquiring under-appreciated, already-characterized drug assets — largely via the FDA's 505(b)(2) pathway, which lets the company reference existing safety and efficacy data rather than run costly ground-up trials — and then commercializing them through an internal sales force targeting pediatric endocrinologists and specialty pharmacies that handle patient reimbursement support. Three of the eight marketed products (Carglumic Acid, Betaine Anhydrous, Nitisinone) are generic versions of already-approved rare-disease drugs, while INCRELEX and GALZIN were acquired and relaunched in December 2024. Manufacturing is fully outsourced to third-party contract manufacturing organizations based mostly in the U.S. and Europe, and the pipeline includes ET-600 (diabetes insipidus), Amglidia (licensed from AMMTeK for neonatal diabetes mellitus, roughly 300 U.S. patients), and the ZENEO needle-free hydrocortisone autoinjector.
Show full overview
Eton's rare-disease pricing is increasingly exposed to federal drug-pricing reform rather than patent-cliff risk, since none of its generic-version products (Carglumic Acid, Betaine Anhydrous, Nitisinone) carry patent protection at all. The 10-K flags that Inflation Reduction Act mechanisms — inflation-based Medicare rebates, the redesigned Part D benefit, and potential future price-negotiation selection — could compress net prices as the product mix and Medicare utilization evolve, even though rare-disease volumes are typically too small today to trigger negotiation. Because ALKINDI SPRINKLE and KHINDIVI are protected only by patents expiring between 2032 and 2043, Eton's medium-term moat rests on formulation exclusivity and 505(b)(2) data protection rather than composition-of-matter patents.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Eton Pharmaceuticals, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Eton Pharmaceuticals, Inc.
Latest news
- NEWS Eton Pharmaceuticals Inc (ETON) Shares Fall 13.0% -- What GF Sco - GuruFocus — GuruFocus negative
- NEWS Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Down 7.4% - Here's Why - MarketBeat — MarketBeat negative
- NEWS Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Down 7.4% - Here's Why - marketbeat.com — marketbeat.com negative
- NEWS Eton Pharmaceuticals (NASDAQ:ETON): High Growth Momentum Meets a Breakout Setup - Chart Mill — Chart Mill positive
- NEWS Analysts Expect Eton Pharmaceuticals, Inc. (NASDAQ:ETON) To Breakeven Soon - Moomoo — Moomoo positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-16Item 5.02MEDIUMJudith Matthews appointed EVP, Accounting and Finance, to succeed James Gruber as CFO, Corporate Secretary and Treasurer effective June 1, 2026. Gruber remains through May 31, 2026 then enters a six-month consulting agreement; clean, planned handoff with successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $49.51. Insider activity concern; also weak momentum, recent C-suite change — blocks BUY_NOW at $51.80. Engine's entry $49.51 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Consecutive earnings misses (2). Chart setup: No clear chart pattern; technical signals are mixed. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.01, quality 7.8/10, growth 10.0/10). | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Target $60.77 (+17.3%), stop $46.91 (−10.4%), A.R:R 1.9:1. Score 6.3/10, moderate confidence.
Take-profit target: $60.77 (+17.3% upside). Target $60.77 (+17.3%), stop $46.91 (−10.4%), A.R:R 1.9:1. Stop-loss: $46.91.
Consecutive earnings misses (2).
Eton Pharmaceuticals, Inc. trades at a P/E of 129.5 (forward 20.3). TrendMatrix value score: 4.9/10. Verdict: Buy (Wait for Entry).
10 analysts cover ETON with a consensus score of 4.1/5. Average price target: $72.
What does Eton Pharmaceuticals, Inc. do?Eton Pharmaceuticals is a commercial-stage rare-disease pharmaceutical company with eight marketed products across...
Eton Pharmaceuticals is a commercial-stage rare-disease pharmaceutical company with eight marketed products across pediatric endocrinology (INCRELEX, ALKINDI SPRINKLE, KHINDIVI) and metabolic disorders (GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, Nitisinone), plus five late-stage pipeline candidates including ET-600, which carries an FDA PDUFA target action date of February 25, 2026. The company relies on third-party contract manufacturers for all products and pursues the FDA's 505(b)(2) pathway, acquiring under-appreciated development assets rather than originating novel compounds